Last edition
News about "Urinary Tract infections "
BARDA Boosts Funding for Basilea's Investigational Oral Antibiotic Targeting Drug-Resistant UTIs
Basilea Pharmaceutica has secured an additional USD 5.4 million from BARDA to accelerate the development of its investigational oral antibiotic ceftibuten-ledaborbactam etzadroxil, a potential treatment for complicated urinary tract infections caused by multidrug-resistant Gram-negative pathogens.
Urinary Tract Infections | 06/08/2026 | By News Bureau
Orchid Pharma Partners with Pharmasyntez to Commercialise Exblifep in Russia
Orchid Pharma has signed an exclusive licensing and supply agreement with Pharmasyntez JSC for Exblifep in Russia. The partnership is expected to strengthen access to advanced antimicrobial therapies while addressing the growing challenge of antibiotic resistance.
Urinary Tract Infections | 09/07/2026 | By News Bureau
Orchid Pharma and Cipla to Launch Cefepime-Enmetazobactam in India
Orchid Pharma has launched its new drug, Cefepime-Enmetazobactam, which has been approved for the treatment of complicated Urinary Tract infections (cUTI), Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP) indications.
Urinary Tract Infections | 29/06/2024 | By Aishwarya | 1046
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy